MaxCyte signs technology license partnership with Genentech for cell therapy programs

The agreement gives Genentech access to MaxCyte’s ExPERT GTx platform and other technologies across research, clinical development and manufacturing workflows for multiple programs.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.